SOLAR-PROMOTION
15.5.2024 15:14:34 CEST | Business Wire | Press release
Climate-neutral power generation from solar and wind will place several new challenges on the energy system. Key is that a significantly higher degree of flexibility will be required compared to today to keep supply and consumption in balance. Flexible consumers can make a significant contribution to this. How this can be achieved will be an important topic at EM-Power Europe, the international trade fair for energy management and integrated energy solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515343343/en/
EM-Power Europe 2024 presents a wide range of solutions for more digitalization and flexibility. (Photo: Solar Promotion GmbH)
"According to EU calculations, the demand for flexibility will increase by 133 percent between now and 2030," explains Michael Villa, Managing Director of the European industry association smartEn. In a recent study, Agora Energiewende came to the conclusion that by 2035, electric cars, heat pumps and home storage systems will be able to shift around ten percent of the annual electricity demand required in Germany. That would accumulate to around 100 terawatt hours. This flexibility on the consumer side will save the economy around 4.8 billion euros. But how can consumers make contributions to the energy transition?
Making ideal use of your own electricity
An initial consumer contribution to flexibilization has been a proven state of the art for years: prosumers with their own photovoltaic system linked to a stationary battery storage system, their own heat pump and charge their electric car with the electricity they generate themselves. This way, they not only minimize their own electricity consumption from the grid - they also reduce the load on the respective distribution grid by maximizing their own consumption.
Supply and demand
When there is a lot of electricity available from the sun and wind, prices on the European trading platform EEX fall. From 2025, all electricity suppliers in Germany will be obliged to offer their customers dynamic tariffs. They will then be able to optimize their consumption in terms of price. However, if many households consume a lot of electricity at the same time, the distribution grids will be under considerable strain. Making grid charges more flexible could counteract this effect: from 2025, grid charges in Germany will be higher at times of high grid utilization and lower at times of low utilization.
Suppliers intervene
Suppliers will also contribute to flexibility to a greater extent: if grid capacity threatens to become scarce, they can reduce their customers' consumption. This is an example that has been successfully practiced: If a bottleneck becomes apparent, suppliers can temporarily switch off connected heat pumps themselves. However, customers do not suffer any loss of comfort as a result, as thermal storage units keep their homes warm. In return, they receive the electricity for their heat pump at a particularly favorable price.
New: throttling instead of switching off
A novelty to the Energy Industry Act (EnWG) allows grid operators to throttle some wallboxes and heat pumps if there is a risk of grid overload. In return, grid operators may no longer refuse to connect such consumers on the grounds of possible grid overload.
EM-Power Europe
EM-Power Europe is the international trade fair for energy management and integrated energy solutions. Under the motto "Empowering Grids and Prosumers", it brings together stakeholders and focuses on current trends and developments. EM-Power Europe will take place from June 19 to 21, 2024 at Messe München.
Further information: www.em-power.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515343343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
